Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
Cash Flow from Operations: $17 million generated in Q3 2024. Cash and Investments: $348.7 million as of September 30, 2024. Gross Margin: 91% for Q3 2024, compared to 88% in Q3 2023. SG&A Expenses: $42.4 million for Q3 2024, down from $47.8 million in Q3 2023. R&D Expenses: $3 million for Q3 2024, down from $13.6 million in Q3 2023. Net Income: $14.4 million for Q3 2024, or $0.10 per share, compared to a net loss of $13.4 million in Q3 2023. Patient Growth: 25% increase in total patients on LUPKYNIS therapy, with approximately 2,422 patients as of September 30, 2024. Restructuring Initiative: Workforce reduction by approximately 45%, with expected annualized cash-based operating expense savings of more than $40 million. Warning! GuruFocus has detected 5 Warning Signs with MTCH. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Aurinia Pharmaceuticals Inc ( NASDAQ:AUPH ) reported a
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024Business Wire
- Aurinia to Participate in Jefferies London Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Aurinia to Participate in Jefferies London Healthcare ConferenceBusiness Wire
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of GrowthBusiness Wire
AUPH
Earnings
- 11/7/24 - Beat
AUPH
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- 11/12/24 - Form 4
- AUPH's page on the SEC website